- Calculate 4Ts before ordering tests. 0–3 = low → HIT very unlikely, don't send the test, keep heparin.
- 4Ts ≥4 → stop ALL heparin (flushes, LMWH, heparin-coated lines) and start a non-heparin anticoagulant — even before results.
- Argatroban (liver OK, kidney failure OK), bivalirudin, fondaparinux, or a DOAC (stable patients).
- No platelet transfusions (unless bleeding). No warfarin until platelets ≥150 k; overlap ≥5 days.
- HIT is pro-thrombotic — check leg Dopplers. Treat 3 months if thrombosis; 4 weeks–3 months if isolated HIT.
Pathophysiology in 60 seconds
⌄
- Heparin binds platelet factor 4 (PF4) → new shape → body makes IgG antibodies against PF4–heparin.
- Antibody complexes activate platelets via FcγRIIa → platelets clump (count falls) and release procoagulants → thrombosis (venous > arterial).
- Platelets low but clotting — the paradox. Bleeding is rare.
- Timing: antibodies need 5–10 days to form (or <1 day if heparin in last 30–100 days — "rapid onset").
Diagnosis — 4Ts
⌄
| 2 points | 1 point | 0 points | |
|---|---|---|---|
| Thrombocytopenia | Fall >50% and nadir ≥20 k | Fall 30–50% or nadir 10–19 k | <30% or nadir <10 k |
| Timing | Day 5–10, or ≤1 day with recent heparin (≤30 d) | >day 10, unclear, or ≤1 day with heparin 30–100 d ago | ≤4 days, no recent heparin |
| Thrombosis | New thrombosis, skin necrosis, systemic reaction after bolus | Progressive/recurrent/suspected | None |
| oTher cause | None | Possible | Definite (sepsis, DIC, drugs, bleed) |
0–3 low · 4–5 intermediate · 6–8 high.
- Intermediate/high → PF4 immunoassay (ELISA). High OD (>1.0–2.0) = more likely.
- Serotonin release assay (SRA) confirms (functional, days).
- Lower-extremity Doppler ultrasound in all confirmed/suspected HIT (silent DVT is common).
Management
⌄
| Drug | Use | Note |
|---|---|---|
| Argatroban | IV; liver clearance → good in renal failure | Raises INR (complicates warfarin switch); reduce in liver disease |
| Bivalirudin | IV; short half-life; renal adjust | Cardiac procedures |
| Fondaparinux | SC daily, weight-based | Avoid CrCl <30 |
| Rivaroxaban / apixaban | Stable patients, no high bleeding risk | Use VTE treatment doses |
- HIT with thrombosis (HITT): 3 months.
- Isolated HIT: at least until platelets recover; many treat 4 weeks–3 months (high early thrombosis risk).
- Warfarin only after platelets ≥150 k; start low, overlap ≥5 days and until INR therapeutic 24 h (risk of venous limb gangrene from protein C drop).
- Avoid heparin in the future when possible; document allergy.
- Cardiac surgery with remote HIT (antibody negative) → brief intra-op heparin is acceptable.
Pitfalls
⌄
- Sending PF4 ELISA on everyone with low platelets (false positives → harm).
- Stopping heparin without starting another anticoagulant.
- Forgetting heparin flushes and coated catheters.
- Transfusing platelets "because count is low."
Board corner
⌄
| Stem | Answer |
|---|---|
| Day 7 of heparin, platelets 220 → 90 k, new DVT | HIT → stop heparin, start argatroban |
| Platelets fall day 2 of heparin, no prior exposure | Not HIT (too early) |
| HIT + CrCl 15 | Argatroban |
| HIT, platelets 60 k, on argatroban, start warfarin? | Wait until ≥150 k |
| Skin necrosis at LMWH injection site | HIT |
References
⌄
- Cuker A, et al. ASH 2018 guidelines for VTE: HIT. Blood Adv. 2018;2:3360.
- Lo GK, et al. 4Ts score. J Thromb Haemost. 2006;4:759.
- Warkentin TE. HIT. NEJM. 2015.